Captor Therapeutics Spolka Akcyjna Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Tom Shepherd
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 4yrs |
| CEO ownership | 1.3% |
| Management average tenure | no data |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Jul 13
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15CEO
Tom Shepherd
4yrs
Tenure
Dr. Thomas Shepherd, Ph D also known as Tom, is Chief Executive Officer at Captor Therapeutics spolka akcyjna and serves as Executive Chairman of Captor Therapeutics's Swiss affiliate, with responsibility...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Member of the Supervisory Board | 1.8yrs | no data | no data | |
| Chief Medical Officer | 2yrs | no data | no data | |
| Chairman of the Supervisory Board | 6.4yrs | no data | 7.72% PLN 16.2m | |
| Independent Member of the Supervisory Board | 3yrs | no data | no data | |
| Independent Member of the Supervisory Board | no data | no data | 0.13% PLN 280.0k | |
| Member of the Supervisory Board | 3.8yrs | no data | 0.13% PLN 280.0k |
3.0yrs
Average Tenure
Experienced Board: CTX's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 05:48 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Captor Therapeutics Spolka Akcyjna is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Lukasz Kosiarski | Ipopema Securities S.A. |